AbbVie ABBV expects to return to robust revenue growth in 2025, despite the U.S. loss of exclusivity (LOE) for its flagship ...

Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...

CVS also announced that AbbVie and CVS-owned company Cordavis, which launched in August, will produce a co-branded version of Humira that will be made available to customers in the second quarter of ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

Please provide your email address to receive an email when new articles are posted on . Simlandi (adalimumab-ryvk) hit the market as first interchangeable, citrate-free Humira biosimilar in a ...

Teva Pharmaceuticals and Alvotech are introducing Simlandi (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to AbbVie’s Humira for the treatment of adult rheumatoid arthritis, ...

Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...

April 5 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s (ABBV.N), opens new tab blockbuster ...

Humira has been one of the world's top selling drugs for more than two decades. But thanks to some new copycats — including one that is being sold at entrepreneur Mark Cuban's online pharmacy — its ...

Inflammatory disorder drug developer Acelyrin has a therapeutic candidate in late-stage development in three different indications—each of them offering the biotech the chance to compete favorably ...